| Size | Price | |
|---|---|---|
| 50mg | ||
| 100mg | ||
| 250mg | ||
| Other Sizes |
| Targets |
L-Methionine-13C5,15N targets the same metabolic pathways as natural methionine, primarily serving as a substrate for protein synthesis and methylation reactions. It is a precursor to S-adenosylmethionine (SAM), the universal methyl donor for numerous transmethylation reactions involving DNA, RNA, proteins, and lipids. As a stable isotope-labeled tracer, its primary application is as an analytical target in quantification assays rather than a pharmacological target itself.
|
|---|---|
| ln Vitro |
This compound does not exhibit pharmacological "activity" in conventional drug screening contexts. Instead, its in vitro utility is as a tracer for studying methionine metabolism. It is used in cell culture media to track metabolic flux through the methionine cycle. Incorporation of this labeled methionine into newly synthesized proteins allows for the measurement of protein synthesis rates. It is also used to study transsulfuration pathways where methionine is converted to cysteine in hepatocytes.
|
| ln Vivo |
In vivo activity of L-Methionine-13C5,15N is limited to its function as a metabolic tracer. When administered to animal models, it is absorbed and distributed identically to natural methionine. It incorporates into tissue proteins and is metabolized to labeled SAM and homocysteine. Researchers quantify these labeled metabolites in plasma or tissue samples to assess whole-body protein turnover, methylation capacity, or specific metabolic fluxes under various physiological or pathological conditions.
|
| Enzyme Assay |
A typical non-cell based assay involves a protein precipitation and derivatization protocol. A biological sample (plasma or serum) is mixed with acetonitrile containing L-Methionine-13C5,15N as an internal standard. After centrifugation to remove precipitated proteins, the supernatant is derivatized using a reagent like phenyl isothiocyanate (PITC). The derivatized sample is then analyzed by LC-MS/MS. The analyte-to-internal standard peak area ratio is calculated to quantify endogenous methionine concentration against a calibration curve.
|
| Cell Assay |
Cells (e.g., hepatocytes or cancer cell lines) are cultured in methionine-free medium supplemented with L-Methionine-13C5,15N. At various time points, cell pellets or lysates are collected. Proteins are hydrolyzed, and the released amino acids are derivatized. Alternatively, cells are lysed directly for metabolite extraction. The ratio of labeled to unlabeled methionine and its metabolites (e.g., SAM, homocysteine) is determined by LC-MS/MS, enabling the calculation of metabolic turnover rates.
|
| Animal Protocol |
Animal experiments typically involve administering a bolus dose of L-Methionine-13C5,15N via intravenous injection or oral gavage in rodents. Blood samples are collected at serial time points (e.g., 0, 15, 30, 60, 120 minutes) post-administration. Tissues such as liver, muscle, or brain are harvested. Isotopic enrichment of methionine and its derivatives in plasma and tissues is measured by GC-MS or LC-MS/MS to trace metabolic pathways and pharmacokinetics.
|
| ADME/Pharmacokinetics |
As a stable isotope-labeled tracer, L-Methionine-13C5,15N is not considered a therapeutic drug and is administered in minute, non-pharmacological quantities. Its pharmacokinetics mirror natural methionine. It exhibits rapid absorption from the gastrointestinal tract, distribution throughout total body water, and metabolism primarily in the liver and kidneys. The elimination half-life is approximately 1-2 hours in rodents. It is transaminated and demethylated, leading to labeled CO2 excretion.
|
| Toxicity/Toxicokinetics |
At the trace doses used for metabolic tracing (microg to mg/kg range), L-Methionine-13C5,15N exhibits negligible toxicity. Toxicity studies are not standard for this reagent. However, based on natural methionine, high doses (multi-gram quantities) can cause hyperhomocysteinemia and potential neurotoxicity. When used as directed for analytical internal standards, the compound poses no significant acute or chronic health risks, though standard laboratory safety precautions for handling fine chemicals apply.
|
| References | |
| Additional Infomation |
As a stable isotope-labeled internal standard, this compound is not an active pharmaceutical ingredient (API) and has no clinical trials or approved drug status. Its primary applications are in bioanalytical chemistry and metabolic research. It is commonly used in protein expression media for NMR spectroscopy (bio-NMR suitable), allowing structural studies of labeled proteins. Its purity specification is typically ≥95% (CP grade) with high optical purity [alpha]25/D +23.1deg in 1 M HCl.
|
| Molecular Formula |
13C5H1115NO2S
|
|---|---|
| Molecular Weight |
155.17
|
| Exact Mass |
155.064
|
| CAS # |
202468-47-1
|
| Related CAS # |
L-Methionine;63-68-3
|
| PubChem CID |
71311580
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
9
|
| Complexity |
97
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[13CH3]S[13CH2][13CH2][13C@@H]([13C](=O)O)[15NH2]
|
| InChi Key |
FFEARJCKVFRZRR-XAFSXMPTSA-N
|
| InChi Code |
InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1/i1+1,2+1,3+1,4+1,5+1,6+1
|
| Chemical Name |
(2S)-2-(15N)azanyl-4-(113C)methylsulfanyl(1,2,3,4-13C4)butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4445 mL | 32.2227 mL | 64.4454 mL | |
| 5 mM | 1.2889 mL | 6.4445 mL | 12.8891 mL | |
| 10 mM | 0.6445 mL | 3.2223 mL | 6.4445 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
